BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 28628466)

  • 1. Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease.
    Shah AA; Rosen A; Hummers LK; May BJ; Kaushiva A; Roden RBS; Armstrong DK; Wigley FM; Casciola-Rosen L; Visvanathan K
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):71-74. PubMed ID: 28628466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer.
    Betteridge ZE; Priest L; Cooper RG; McHugh NJ; Blackhall F; Lamb JA
    Arthritis Res Ther; 2018 Aug; 20(1):176. PubMed ID: 30092841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
    Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
    Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
    Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
    Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies in scleroderma and polymyositis: an update.
    McCarty GA
    Semin Dermatol; 1991 Sep; 10(3):206-16. PubMed ID: 1931570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and serological associations of autoantibodies to the Ku70/Ku80 heterodimer determined by a novel chemiluminescent immunoassay.
    Mahler M; Swart A; Wu J; Szmyrka-Kaczmarek M; Senécal JL; Troyanov Y; Hanly JG; Fritzler MJ
    Lupus; 2016 Jul; 25(8):889-96. PubMed ID: 27252266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibodies and Cancer Association: the Case of Systemic Sclerosis and Dermatomyositis.
    Fiorentino DF; Casciola-Rosen L
    Clin Rev Allergy Immunol; 2022 Dec; 63(3):330-341. PubMed ID: 35593962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brief Report: Anti-RNPC-3 Antibodies As a Marker of Cancer-Associated Scleroderma.
    Shah AA; Xu G; Rosen A; Hummers LK; Wigley FM; Elledge SJ; Casciola-Rosen L
    Arthritis Rheumatol; 2017 Jun; 69(6):1306-1312. PubMed ID: 28217959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma.
    Shah AA; Hummers LK; Casciola-Rosen L; Visvanathan K; Rosen A; Wigley FM
    Arthritis Rheumatol; 2015 Apr; 67(4):1053-61. PubMed ID: 25605296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of clinical characteristics and laboratory parameters of patients with dermatomyositis-specific autoantibodies and autoantibody-negative patients].
    Bodoki L; Budai D; Nagy-Vincze M; Griger Z; Betteridge Z; Dankó K
    Orv Hetil; 2015 Sep; 156(36):1451-9. PubMed ID: 26320599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Autoantibodies in systemic sclerosis and their clinical correlation in patients from a Midwestern region of Brazil].
    Coelho Horimoto AM; da Costa IP
    Rev Bras Reumatol; 2015; 55(3):229-39. PubMed ID: 25559063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Polymyositis/scleroderma autoantibody-positive scleroderma with dermatomyositis (scleromyositis)].
    Török L; Dankó K; Cserni G; Szücs G
    Orv Hetil; 2002 Nov; 143(45):2553-6. PubMed ID: 12501562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies.
    Rönnelid J; Barbasso Helmers S; Storfors H; Grip K; Rönnblom L; Franck-Larsson K; Nordmark G; Lundberg IE
    Autoimmun Rev; 2009 Sep; 9(1):58-61. PubMed ID: 19285154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnostic significance of scleroderma and myositis-associated autoantibodies].
    Genth E; Mierau R
    Z Rheumatol; 1995; 54(1):39-49. PubMed ID: 7725809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis.
    Betteridge ZE; Gunawardena H; Chinoy H; North J; Ollier WE; Cooper RG; McHugh NJ;
    Ann Rheum Dis; 2009 Oct; 68(10):1621-5. PubMed ID: 18930994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
    Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
    Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy.
    Ichimura Y; Matsushita T; Hamaguchi Y; Kaji K; Hasegawa M; Tanino Y; Inokoshi Y; Kawai K; Kanekura T; Habuchi M; Igarashi A; Sogame R; Hashimoto T; Koga T; Nishino A; Ishiguro N; Sugimoto N; Aoki R; Ando N; Abe T; Kanda T; Kuwana M; Takehara K; Fujimoto M
    Ann Rheum Dis; 2012 May; 71(5):710-3. PubMed ID: 22258483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer.
    Igusa T; Hummers LK; Visvanathan K; Richardson C; Wigley FM; Casciola-Rosen L; Rosen A; Shah AA
    Ann Rheum Dis; 2018 Aug; 77(8):1179-1186. PubMed ID: 29678941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies.
    Cavazzana I; Fredi M; Taraborelli M; Quinzanini M; Tincani A; Franceschini F
    Clin Exp Rheumatol; 2013; 31(2 Suppl 76):118-21. PubMed ID: 23910615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoantibody Markers of Increased Risk of Malignancy in Patients with Dermatomyositis.
    Marzęcka M; Niemczyk A; Rudnicka L
    Clin Rev Allergy Immunol; 2022 Oct; 63(2):289-296. PubMed ID: 35147864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.